Attila C.
- Country
- Hungary
- Department
- 3603: Szivgyogyaszati Klinika
Research Overview
- Efficacy and Safety of Early In-Hospital Inclisiran Initiation in Patients with Acute Coronary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Study
- Evaluation of Pelacarsen (TQJ230) in Reducing Major Cardiovascular Events in Patients with Established Cardiovascular Disease: A Randomized, Double-Blind, Placebo-Controlled Trial
- Efficacy and Safety Comparison of SRSD107 and Enoxaparin in Preventing Venous Thromboembolism in Elective Unilateral Total Knee Arthroplasty
Data & Insights
Has run more than one trial at 11 of 338 partner sites.
Specializations
Cardiovascular Medicine
The investigator specializes in the study of cardiovascular disease and its clinical management, with a particular focus on lipid disorders and their impact on heart health.
- Lipoprotein Research
- Cardiovascular Risk Assessment
- Major Adverse Cardiovascular Events
Their research interests extend to preventive cardiology and innovative therapeutic approaches for reducing cardiovascular risk factors.
Lipid Management
This investigator has developed expertise in lipoprotein disorders, specifically focusing on the role of lipoprotein(a) in cardiovascular health.
- Lipid-Lowering Therapies
- Biomarker Analysis
- Treatment Optimization
Their work encompasses the evaluation of novel therapeutic approaches for managing elevated lipoprotein levels.
Clinical Outcomes
The investigator focuses on evaluating cardiovascular outcomes, including myocardial infarction, stroke, and the need for coronary revascularization.
- Cardiovascular Mortality
- Emergency Interventions
- Long-term Patient Outcomes
Their research contributes to understanding the relationship between therapeutic interventions and cardiovascular event prevention.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.